Ab­b­Vie's Gon­za­lez: Skyrizi and Rin­voq to be­come Hu­mi­ra 2.0 — while adding an in­di­ca­tion for atopic der­mati­tis

While Ab­b­Vie’s Hu­mi­ra still holds the crown for the best-sell­ing non-Covid drug last year, the Big Phar­ma has its eyes on Hu­mi­ra’s po­ten­tial suc­ces­sor. Scratch …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER